Compass Therapeutics Shares Outstanding vs. Shares Owned By Institutions
| CMPX Stock | USD 1.63 0.07 4.49% |
For Compass Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Compass Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Compass Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Compass Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Compass Therapeutics over time as well as its relative position and ranking within its peers.
Compass |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compass Therapeutics. If investors know Compass will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Compass Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.35) | Revenue Per Share 0.006 | Return On Assets (0.22) | Return On Equity (0.32) |
The market value of Compass Therapeutics is measured differently than its book value, which is the value of Compass that is recorded on the company's balance sheet. Investors also form their own opinion of Compass Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Compass Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compass Therapeutics' market value can be influenced by many factors that don't directly affect Compass Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Compass Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Compass Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compass Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Compass Therapeutics Shares Owned By Institutions vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Compass Therapeutics's current stock value. Our valuation model uses many indicators to compare Compass Therapeutics value to that of its competitors to determine the firm's financial worth. Compass Therapeutics is number one stock in shares outstanding category among its peers. It is rated second in shares owned by institutions category among its peers . The ratio of Shares Outstanding to Shares Owned By Institutions for Compass Therapeutics is about 1,988,568 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Compass Therapeutics' earnings, one of the primary drivers of an investment's value.Compass Shares Owned By Institutions vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Compass Therapeutics |
| = | 137.59 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Compass Therapeutics |
| = | 69.19 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Compass Shares Owned By Institutions Comparison
Compass Therapeutics is currently under evaluation in shares owned by institutions category among its peers.
Compass Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Compass Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Compass Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Compass Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Compass Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 37 K | 38.9 K | |
| Net Interest Income | 7.9 M | 8.3 M | |
| Interest Income | 7.9 M | 8.3 M | |
| Operating Income | -50.4 M | -52.9 M | |
| Net Loss | -42.5 M | -44.6 M | |
| Income Before Tax | -42.5 M | -44.6 M | |
| Total Other Income Expense Net | 7.9 M | 8.3 M | |
| Net Loss | -35.3 M | -37.1 M | |
| Net Loss | -42.5 M | -44.6 M | |
| Income Tax Expense | -2.2 M | -2.1 M | |
| Non Operating Income Net Other | 2.8 M | 2.9 M | |
| Change To Netincome | 6 M | 5.7 M | |
| Net Loss | (0.33) | (0.35) | |
| Income Quality | 0.96 | 0.87 | |
| Net Income Per E B T | 1.08 | 1.09 |
Compass Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Compass Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Compass Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Compass Therapeutics' important profitability drivers and their relationship over time.
Use Compass Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Compass Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Compass Therapeutics will appreciate offsetting losses from the drop in the long position's value.Compass Therapeutics Pair Trading
Compass Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Compass Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Compass Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Compass Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Compass Therapeutics to buy it.
The correlation of Compass Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Compass Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Compass Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Compass Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Compass Therapeutics position
In addition to having Compass Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Beers Thematic Idea Now
Beers
Companies involved in production and distribution of domestic and international beer. The Beers theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Beers Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.